How to Buy Neurocrine Biosciences Stock

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences stock last closed at $129.85, up 0.05% from the previous day, and has increased 16.46% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.46 percentage points. Neurocrine Biosciences stock is currently +54.16% from its 52-week low of $84.23, and -18.93% from its 52-week high of $160.18.

There are currently 100.36M NBIX shares outstanding. The market cap of NBIX is $13.03B. In the last 24 hours, 915,000 NBIX shares were traded.

How to Buy Neurocrine Biosciences Stock

Wondering how to invest in Neurocrine Biosciences stock? Here's how.

  1. Choose where to buy Neurocrine Biosciences stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Neurocrine Biosciences stock.
  2. Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
  3. Put funds into your brokerage account: Choose your method of payment and add your details.
  4. Analyze Neurocrine Biosciences stock: The Neurocrine Biosciences ticker symbol is NBIX. Is Neurocrine Biosciences stock a good investment? Should you buy shares of NBIX? How do NBIX's underlying business fundamentals look? Do top analysts think Neurocrine Biosciences is a good buy? Why has NBIX's stock price moved recently? (Hint: Our stock research website can help you evaluate if NBIX is a good stock to buy).
  5. Execute your NBIX purchase: Decide if you will purchase NBIX shares at the current market price or use a limit order to purchase NBIX shares at a particular price.
  6. Get notifications regarding your NBIX position: Create a watchlist to track your investment in Neurocrine Biosciences shares.

Step 1: Choose where to buy Neurocrine Biosciences stock

You need an online brokerage account to access the NASDAQ market and buy NBIX shares.

A brokerage account enables you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.

Our preferred brokerage: eToro

Based on our research, eToro is the best place to buy stocks. Here's why:

  • You can invest in stocks with 0% commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
  • Access to global markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
  • Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other financial assets: Such as ETFs and cryptos.

Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Sign up for your brokerage account

Now that you've picked your brokerage, the next step is to fill out some personal info so you are able to buy NBIX today.

How to Create a New Account on eToro

  1. Click here to get started.
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
  2. Enter your personal data to create your new brokerage account.
  1. Submit your application by clicking the "Create Account" button.
  2. Get started with eToro today
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 3: Put funds into your brokerage account

Now that you've finished signing up on a good stock buying app, you need to deposit funds:

Watch the tutorial below to see the process of transferring money into your new investment account.

Get started with eToro today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 4: Analyze Neurocrine Biosciences stock

Once you have identified the best place to buy Neurocrine Biosciences stock, it's very important to evaluate their stock before you invest, so you actually understand the risk as well as the upside.

Neurocrine Biosciences stock at a glance

NBIX Price
$129.85
1w %
-0.06%
1y %
16.46%
5y %
37.29%
P/E
27x
P/B
4.01x
P/S
4.52x
PEG
0.9x
Revenue
$2.86B
Earnings
$478.60M
Fore. Rev. Growth
14.11%
Fore. Earn. Growth
29.86%
Market Cap
$13.03B
Next Earnings
May 6, 2026
Next Dividend
N/A

NBIX Due Diligence Checks

WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.

You can view all of the due diligence checks on NBIX's stock page.

How is NBIX stock valued?

Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NBIX's intrinsic value.

Using relative valuations measures:

  • NBIX could be undervalued based on its P/E ratio of 27x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of -103.14x
  • NBIX may be overvalued based on its P/B ratio of 4.01x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.6x
  • NBIX may be undervalued based on its PEG ratio of 0.9x

You can access more valuation analysis on NBIX's stock here.

Is NBIX a healthy company?

Signs that NBIX is financially healthy:

  • NBIX profit margin has gone up from 14.5% to 16.7% in the past year.
  • Total NBIX debt is lower than 5 years ago, relative to shareholder equity.
  • There are more short-term assets than long-term liabilities on the NBIX balance sheet.
  • There are more short-term assets than short-term liabilities on the NBIX balance sheet.
  • NBIX earnings of $705.40M is not enough to cover its interest payments.
  • NBIX's operating cash flow of $782.70M allows it to safely service it's debt of $415.30M.

Signs that NBIX is not financially healthy:

  • NBIX has a relatively high debt to equity ratio of 0.42.

Is NBIX stock a Buy, Hold, or Sell, according to Wall Street analysts?

Out of 17 Equities analysts who research NBIX, the consensus analyst rating on Neurocrine Biosciences is a Strong Buy

Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.

Most Recent NBIX Analyst Forecasts

Brian Abrahams, a top 15% analyst from RBC Capital maintains NBIX with a buy rating and lowers their NBIX price target from $180.00 to $177.00, on Feb 12, 2026.

Evan Seigerman, a top 25% analyst from BMO Capital maintains NBIX with a hold rating and lowers their NBIX price target from $147.00 to $140.00, on Feb 12, 2026.

Laura Chico, a top 5% analyst from Wedbush maintains NBIX with a buy rating and raises their NBIX price target from $149.00 to $151.00, on Feb 12, 2026.

Andrew S. Fein, a top 15% analyst from HC Wainwright & Co. maintains NBIX with a buy rating and lowers their NBIX price target from $198.00 to $192.00, on Feb 12, 2026.

Ami Fadia, a top 1% analyst from Needham maintains NBIX with a buy rating and lowers their NBIX price target from $187.00 to $185.00, on Feb 12, 2026.

Needham's Ami Fadia lowered their price target on Neurocrine Biosciences (NASDAQ: NBIX) by 1.1% from $187 to $185 on 2026/02/12. The analyst maintained their Buy rating on the stock.

Neurocrine Biosciences reported its Q4 and FY 2025 earnings.

Cutting their price target, Fadia spotlighted that management guided strong double-digit Ingrezza growth, in line with the $2.72B consensus, and expressed optimism regarding Crenessity's growth trajectory this year.

Looking ahead, the analyst said the company's pipeline is chock-a-block, with two Phase 3 programs currently underway and potential to deliver one new medicine every two years.

Earnings Report

Neurocrine Biosciences reported:

For Q4 2025:

  • EPS of $1.88, which missed the Zacks Consensus Estimate of $2.25 and Q4 2024's $1.69.
  • Revenue of $805.5M, which beat the Zacks Consensus Estimate by 2.89% and Q4 2024's $627.7M.

For FY 2025:

  • EPS of $6.39, up from FY 2024's $6.33.
  • Revenue of $2.86B, up from FY 2024's $2.36B.

For FY 2026, management guided:

  • INGREZZA Net Product Sales of $2.7B to $2.8B.

CEO Kyle W. Gano, Ph.D., commented: "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, more diversified biopharmaceutical company.

"In 2026, we are focused on delivering strong, sustainable growth for INGREZZA and CRENESSITY® (crinecerfont) while advancing our pipeline anchored by Phase 3 programs, including osavampator in major depressive disorder and direclidine in schizophrenia.

"We expect this building momentum will create value for all stakeholders as Neurocrine is well positioned to improve the lives of even more patients in the years ahead."

You can dive deeper into what analysts are forecasting on the Neurocrine Biosciences stock forecast page.

NBIX Technicals

SMA10
129.91
SMA20
129.99
SMA50
133.35
SMA100
140.07
SMA200
136.85
MACD
-1.33
MACD Signal
-1.51
MACD Histogram
0.18
RSI
46.23
Stochastic %K
29.43
Stochastic %D
29.44
StochRSI %K
37.7
StochRSI %D
34.38

NBIX Performance Metrics

Last year, NBIX earnings were $478.60M. Over the past 5 year, NBIX's earnings have gone up by 1.89% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 9.21%.

Last year, NBIX revenue was $2.86B. Over the last five year, NBIX's revenue has grown by 22.29% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 6.56%.

Dig into NBIX's earnings and revenue performance here.

Are NBIX executives and large shareholders buying or selling the stock?

In the past year, insiders at NBIX have sold more shares than they have bought.

Matt Abernethy, Chief Financial Officer of NBIX, was the latest NBIX insider to sell. They sold $150,185.20 worth of NBIX shares on Feb 13, 2026.

Dig into more about who owns NBIX stock here.

Does NBIX provide a stable income stream?

No, Neurocrine Biosciences doesn't provide an income stream by paying out dividends.

Get analysis from other traders

One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.

Click below to find out what other community members have to say.

Step 5: Execute your NBIX purchase

There are two primary order types:

  • Market order: A market order is an order to buy or sell a stock at the best possible price.
    Market orders are generally fine for most investors.
  • Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
    If you want to be certain you're buying or selling at a specific price limit, use a limit order.

Press the Open button and your broker will place the order.

If you require additional help with buying stocks on eToro, click the how to video below:

Open eToro Account

Step 6: Get notifications regarding your NBIX position

Now that you own some shares in NBIX, you'll want to keep up with your company.

Add NBIX to a watchlist to track the latest developments regarding your NBIX stock.

NBIX Feed

How to Buy Stock in Neurocrine Biosciences

To summarize, here are the 6 steps to buy Neurocrine Biosciences stock:

  1. Choose where to buy Neurocrine Biosciences stock
  2. Sign up for your brokerage account
  3. Put funds into your brokerage account
  4. Analyze Neurocrine Biosciences stock
  5. Execute your NBIX purchase
  6. Get notifications regarding your NBIX position

If you need a online brokerage, eToro is our favorite venue.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

If you want to get the latest news on your new investment in Neurocrine Biosciences, get started below.

NASDAQ: NBIX
$129.85+0.07 (+0.05%)
Updated Mar 16, 2026
Open eToro Account
Your capital is at risk.
NASDAQ: NBIX
$129.85+0.07 (+0.05%)
Updated Mar 16, 2026
Open eToro Account
Your capital is at risk.

FAQ

How much does it cost to buy one Neurocrine Biosciences share?

As of Mar 16, 2026, it costs $129.85 to buy one share of Neurocrine Biosciences stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.077 shares of NBIX.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Is now a good time to buy Neurocrine Biosciences stock?

According to 17 Wall Street analysts who monitor Neurocrine Biosciences, their consensus recommendation is to buy Neurocrine Biosciences stock.

What is the best way to buy Neurocrine Biosciences stock?

One way to place an order for Neurocrine Biosciences stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.